litlas
Log inCreate account

Mark E. Gurney

Active 1980–2025

83
Papers
22,892
Citations
63
h-index
79
i10-index

Citations

Citations per year for Mark E. Gurney1951: 1 citations1980: 1 citations1981: 7 citations1982: 4 citations1983: 7 citations1984: 14 citations1985: 18 citations1986: 15 citations1987: 29 citations1988: 71 citations1989: 46 citations1990: 39 citations1991: 36 citations1992: 20 citations1993: 18 citations1994: 19 citations1995: 46 citations1996: 83 citations1997: 121 citations1998: 139 citations1999: 176 citations2000: 210 citations2001: 243 citations2002: 300 citations2003: 386 citations2004: 395 citations2005: 336 citations2006: 350 citations2007: 341 citations2008: 371 citations2009: 330 citations2010: 276 citations2011: 307 citations2012: 250 citations2013: 204 citations2014: 193 citations2015: 156 citations2016: 133 citations2017: 130 citations2018: 94 citations2019: 339 citations2020: 325 citations2021: 379 citations2022: 350 citations2023: 209 citations2024: 314 citations2025: 181 citations2026: 6 citations1952–1979: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,095 citing papers, 34.6% of this breakdownUnited Kingdom: 671 citing papers, 7.5% of this breakdownGermany: 509 citing papers, 5.7% of this breakdownChina: 504 citing papers, 5.6% of this breakdownItaly: 420 citing papers, 4.7% of this breakdownCanada: 364 citing papers, 4.1% of this breakdownJapan: 360 citing papers, 4% of this breakdownFrance: 276 citing papers, 3.1% of this breakdownAustralia: 243 citing papers, 2.7% of this breakdownSweden: 232 citing papers, 2.6% of this breakdownNetherlands: 202 citing papers, 2.3% of this breakdownSpain: 167 citing papers, 1.9% of this breakdown
0%34.6%Other 21.2%

Institutions

Fields

  • Medicine54.7%
  • Biochemistry, Genetics and Molecular Biology27.9%
  • Neuroscience8.7%
  • Immunology and Microbiology3.8%
  • Computer Science1.3%
  • Nursing1.3%
  • Other2.3%

Topics

  • Amyotrophic Lateral Sclerosis Research9.3%
  • Alzheimer's disease research and treatments6.7%
  • Neurogenetic and Muscular Disorders Research5%
  • Cholinesterase and Neurodegenerative Diseases3.6%
  • Parkinson's Disease Mechanisms and Treatments2.9%
  • Computational Drug Discovery Methods2.2%
  • Other70.3%

Coauthors

All papers

Open in search
  1. Motor Neuron Degeneration in Mice that Express a Human Cu,Zn Superoxide Dismutase Mutation

    Authors: Mark E. Gurney, Haifeng Pu, Arlene Y. Chiu, Mauro C. Dal Canto, Cynthia Y. Polchow, Denise D. Alexander, Jan Caliendo, Afif Hentati, Young W. Kwon, Han‐Xiang Deng, Wenje Chen, Ping Zhai, Robert Sufit, Teepu Siddique - Science 1994 cited by 4,158

  2. Associations of semaglutide with first‐time diagnosis of Alzheimer's disease in patients with type 2 diabetes: Target trial emulation using nationwide real‐world data in the US

    Authors: William Yang Wang, QuangQiu Wang, Xin Qi, Mark E. Gurney, George Perry, Nora D. Volkow, Pamela B. Davis, David C. Kaelber, Rong Xu - Alzheimer s & Dementia 2024 cited by 141

  3. Inhibition of phosphodiesterase-4D in adults with fragile X syndrome: a randomized, placebo-controlled, phase 2 clinical trial

    Authors: Elizabeth Berry‐Kravis, Mark Harnett, Scott A. Reines, Melody Reese, Lauren E. Ethridge, Abigail H. Outterson, Claire Michalak, Jeremiah Furman, Mark E. Gurney - Nature Medicine 2021 cited by 131

  4. CD38 knockout natural killer cells expressing an affinity optimized CD38 chimeric antigen receptor successfully target acute myeloid leukemia with reduced effector cell fratricide

    Authors: Mark E. Gurney, Arwen Stikvoort, Emma Nolan, Lucy Kirkham-McCarthy, Stanislav Khoruzhenko, Rama Shivakumar, Sonja Zweegman, Niels W.C.J. van de Donk, Tuna Mutis, Éva Szegezdi, Subhashis Sarkar, Michael O’Dwyer - Haematologica 2020 cited by 110

  5. Tumor Necrosis Factor (TNF) blocking agents are associated with lower risk for Alzheimer’s disease in patients with rheumatoid arthritis and psoriasis

    Authors: Mengshi Zhou, Rong Xu, David C. Kaelber, Mark E. Gurney - PLoS ONE 2020 cited by 153

  6. COVID‐19 and dementia: Analyses of risk, disparity, and outcomes from electronic health records in the US

    Authors: QuanQiu Wang, Pamela B. Davis, Mark E. Gurney, Rong Xu - Alzheimer s & Dementia 2021 cited by 273

  7. A variant in CDKAL1 influences insulin response and risk of type 2 diabetes

    Authors: Valgerður Steinthórsdóttir, Guðmar Þorleifsson, Inga Reynisdóttir, Rafn Benediktsson, Þorbjörg Jónsdóttir, G. Bragi Walters, Unnur Styrkársdóttir, Sólveig Grétarsdóttir, Valur Emilsson, Shyamali Ghosh, Adam Baker, Steinunn Snorradóttir, Hjördis Bjarnason, Maggie Ng, Torben Hansen, Yu Z. Bagger, Robert L. Wilensky, Muredach P. Reilly, Adebowale Adeyemo, Yuanxiu Chen, Jie Zhou, Vilmundur Guðnason, Guanjie Chen, Hanxia Huang, Kerrie Lashley, Ayo P. Doumatey, Wing‐Yee So, Ronald C.W., Gitte Andersen, Knut Borch‐Johnsen, Torben Jørgensen, Jana V. van Vliet‐Ostaptchouk, Marten H. Hofker, Cisca Wijmenga, Claus Christiansen, Daniel J. Rader, Charles N. Rotimi, Mark E. Gurney, Juliana C.N. Chan, Oluf Pedersen, Gunnar Sigurðsson, Jeffrey R. Gulcher, Unnur Þorsteinsdóttir, Augustine Kong, Kāri Stefánsson - Nature Genetics 2007 cited by 1,085

  8. Concurrent transposon engineering and CRISPR/Cas9 genome editing of primary CLL-1 chimeric antigen receptor–natural killer cells

    Authors: Mark E. Gurney, Eimear O’Reilly, Sarah Corcoran, Sarah Brophy, Janusz Krawczyk, Neil Otto, David Hermanson, Richard Childs, Éva Szegezdi, Michael O’Dwyer - Cytotherapy 2022 cited by 38

  9. Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety

    Authors: Alex B. Burgin, Ólafur Þ. Magnússon, Jasbir Singh, Pam Witte, Bart L. Staker, Jón Már Björnsson, Margrét Þorsteinsdóttir, Sigrún Hrafnsdóttir, Timothy J. Hagen, Alex S. Kiselyov, Lance Stewart, Mark E. Gurney - Nature Biotechnology 2009 cited by 394

  10. Features and Factors Associated With Myeloid Neoplasms After Chimeric Antigen Receptor T-Cell Therapy

    Authors: Mark E. Gurney, Anmol Baranwal, Allison Rosenthal, Mohamed A. Kharfan‐Dabaja, Saad S. Kenderian, Yi Lin, Mithun Vinod Shah - JAMA Oncology 2024 cited by 24

  11. Feeder Cells at the Interface of Natural Killer Cell Activation, Expansion and Gene Editing

    Authors: Mark E. Gurney, Soumyadipta Kundu, Shubham Pandey, Michael O’Dwyer - Frontiers in Immunology 2022 cited by 47

  12. Membrane-anchored aspartyl protease with Alzheimer's disease β-secretase activity

    Authors: Riqiang Yan, Michael J. Bienkowski, Mary E. Shuck, Huiyi Miao, Monica C. Tory, Adele M. Pauley, John R. Brashler, Nancy C. Stratman, W. Rodney Mathews, Allen E. Buhl, Donald B. Carter, Alfredo G. Tomasselli, L. Parodi, Robert L. Heinrikson, Mark E. Gurney - Nature 1999 cited by 1,434

  13. Phosphodiesterase-4 (PDE4) Molecular Pharmacology and Alzheimer's Disease

    Authors: Mark E. Gurney, Emily C. D’Amato, Alex B. Burgin - Neurotherapeutics 2014 cited by 118

  14. Design and Synthesis of Selective Phosphodiesterase 4D (PDE4D) Allosteric Inhibitors for the Treatment of Fragile X Syndrome and Other Brain Disorders

    Authors: Mark E. Gurney, Richard A. Nugent, Xuesheng Mo, Janice A. Sindac, Timothy J. Hagen, David Fox, James M. O’Donnell, Chong Zhang, Ying Xu, Han‐Ting Zhang, Vincent E. Groppi, Marc B. Bailie, Ronald E. White, Donna L. Romero, A. Samuel Vellekoop, Joel R. Walker, Matthew D. Surman, Lei Zhu, Robert F. Campbell - Journal of Medicinal Chemistry 2019 cited by 74

  15. Realizing Innate Potential: CAR-NK Cell Therapies for Acute Myeloid Leukemia

    Authors: Mark E. Gurney, Michael O’Dwyer - Cancers 2021 cited by 37

  16. Gut–microbiota–microglia–brain interactions in Alzheimer’s disease: knowledge-based, multi-dimensional characterization

    Authors: QuanQiu Wang, Pamela B. Davis, Xin Qi, Shu G. Chen, Mark E. Gurney, George Perry, P. Murali Doraiswamy, Rong Xu - Alzheimer s Research & Therapy 2021 cited by 32

  17. aph-1 and pen-2 Are Required for Notch Pathway Signaling, γ-Secretase Cleavage of βAPP, and Presenilin Protein Accumulation

    Authors: Ross S. Francis, Garth McGrath, Jianhua Zhang, David A. Ruddy, Mary Sym, Javier Apfeld, Monique Nicoll, Mark Maxwell, Bing Hai, Michael C. Ellis, Annette L. Parks, Wei Xu, Jinhe Li, Mark E. Gurney, Richard L. Myers, Carol S. Himes, Ronald R. Hiebsch, Cara Ruble, Jeffrey S. Nye, Daniel Curtis - Developmental Cell 2002 cited by 796

  18. Potential long‐term effect of tumor necrosis factor inhibitors on dementia risk: A propensity score matched retrospective cohort study in US veterans

    Authors: Chunlei Zheng, Nathanael R. Fillmore, Jaime Ramos‐Cejudo, Mary T. Brophy, Ricardo S. Osorio, Mark E. Gurney, Wei Qiao Qiu, Rhoda Au, George Perry, Maureen Dubreuil, Shu G. Chen, Xin Qi, Pamela B. Davis, Nhan Do, Rong Xu - Alzheimer s & Dementia 2021 cited by 26

  19. PDE4 subtypes in cancer

    Authors: Samuel H. Lai, Guston Zervoudakis, Jesse Chou, Mark E. Gurney, Kelly M. Quesnelle - Oncogene 2020 cited by 99

  20. Generating natural killer cells for adoptive transfer: expanding horizons

    Authors: Soumyadipta Kundu, Mark E. Gurney, Michael O’Dwyer - Cytotherapy 2021 cited by 76

  21. Neuregulin 1 and Susceptibility to Schizophrenia

    Authors: Hreinn Stefánsson, Hannes Pétursson, Engilbert Sigurðsson, Valgerður Steinthórsdóttir, Soley Bjornsdottir, Thordur Sigmundsson, Shyamali Ghosh, Jon Brynjolfsson, Steinunn Gunnarsdottir, Omar Ivarsson, Thomas T. Chou, Ómar Hjaltason, Birgitta Birgisdottir, Helgi Jónsson, Vala G Gudnadottir, Elsa Gudmundsdottir, Ásgeir Björnsson, Brynjolfur Ingvarsson, Andrés Ingason, Sigmundur Sigfússon, Hrönn Harðardóttir, Richard P. Harvey, Donna Lai, Mingdong Zhou, Daniela Brunner, Vincent Mutel, Acuna Gonzalo, Greg Lemke, Jesús Sainz, G Jóhannesson, Þorkell Andrésson, Daníel F. Guðbjartsson, Andrei Manolescu, Michael L. Frigge, Mark E. Gurney, Augustine Kong, Jeffrey R. Gulcher, Kāri Stefánsson - The American Journal of Human Genetics 2002 cited by 1,689

  22. Formation of high molecular weight complexes of mutant Cu,Zn-superoxide dismutase in a mouse model for familial amyotrophic lateral sclerosis

    Authors: Jennifer Johnston, Muffie J. Dalton, Mark E. Gurney, Ron R. Kopito - National Academy of Sciences, Proceedings of the National Academy of Sciences 2000 cited by 599

  23. Transgenic mice carrying a human mutant superoxide dismutase transgene develop neuronal cytoskeletal pathology resembling human amyotrophic lateral sclerosis lesions.

    Authors: Pang‐Hsien Tu, P Raju, Kent A. Robinson, Mark E. Gurney, John Q. Trojanowski, V M Lee - National Academy of Sciences, Proceedings of the National Academy of Sciences 1996 cited by 412

  24. Structural basis for the design of selective phosphodiesterase 4B inhibitors

    Authors: David Fox, Alex B. Burgin, Mark E. Gurney - Cellular Signalling 2013 cited by 104